Does Your DNA Decide How You Metabolize Steroids and Meds?

You already paid for a DNA test. Most people who spat into a 23andMe tube did it for an ancestry pie chart, looked at it once, and forgot the file exists. That file holds something far more useful than what percent Viking you are: it holds the variants that decide how fast your liver clears a drug, whether tamoxifen will actually work for your PCT, and whether a GLP-1 is a bad idea for you specifically.

The standard doses printed on every protocol were built for an average metabolism. You are not the average. Roughly 1 in 10 people of European ancestry barely activates tamoxifen. About 1 in 4 carries a variant that turns simvastatin into a muscle-wrecking liability. None of them know it, because nobody told them to look. This guide covers what your raw DNA file can tell you about how you process compounds and medications, what it tells you about training and injury, and just as importantly, what it cannot tell you. VitalMetrics has a free tool that reads the file in your browser, so let's start there.

What your raw DNA file actually is (and why it should never leave your device)

When you tested with 23andMe, AncestryDNA, MyHeritage or FamilyTreeDNA, the lab did not sequence your whole genome. It ran a genotyping array that checks several hundred thousand specific positions, called SNPs, where humans are known to differ. You can download that data as a plain text file from your provider's settings. It is just rows: an SNP ID, a chromosome, a position, and the two letters you inherited.

That file is the most sensitive document you own. It identifies you, your relatives, and your disease risks permanently. So the first rule of analyzing it is simple: do not hand it to a random website. The 23andMe bankruptcy in 2025 and the subsequent change of ownership taught a lot of people that genetic data is an asset that gets sold. Most third-party analysis sites require you to upload the file to their servers.

VitalMetrics does the opposite. The DNA tool parses and analyzes the file using JavaScript running inside your own browser tab. The data never touches a server, never gets stored, and disappears when you close the tab. You get the interpretation; nobody else gets the file. For a document this permanent, that distinction matters more than any single result inside it.

How to download your raw data

The exact path changes as providers update their interfaces, but the logic is the same everywhere. You are looking for a "raw data" or "download DNA data" option, not the polished reports.

• 23andMe: Profile, then Settings, scroll to "23andMe Data", and request the raw data download. You will get an email with a link to a .txt file.
• AncestryDNA: Settings on your DNA results, then "Download Raw DNA Data". It arrives as a zipped file you unzip to a .txt.
• MyHeritage: Manage DNA kits, then the three-dot menu, then "Download". It exports a CSV.
• FamilyTreeDNA: Sign in, go to the autosomal (Family Finder) results, and download the raw data.

The VitalMetrics tool auto-detects which of these four formats you uploaded, so you do not need to convert anything. One caveat: a few clinically important probes, including the main cystic fibrosis variant, are reported by 23andMe under internal "i" identifiers rather than standard rs numbers. The tool reads those aliases too, which many basic parsers miss.

Pharmacogenomics: the genes that decide how you process drugs

This is the part with real, actionable consequences. Pharmacogenomics studies how your genes change drug response, and for this audience it is the most underused data in your file. The core idea: for each drug-processing enzyme you are classified somewhere on a spectrum, poor metabolizer, intermediate, normal, or ultrarapid. Where you land changes the dose that is right for you.

CYP2D6 and whether your tamoxifen PCT actually works

Tamoxifen is a prodrug. It does almost nothing until the liver enzyme CYP2D6 converts it into endoxifen, the metabolite that actually does the work. If your CYP2D6 is broken, your tamoxifen is mostly inert.

This is not a small effect. Reduced-function CYP2D6 carriers generate several-fold less endoxifen than normal metabolizers, and most poor metabolizers fall below the therapeutic threshold of roughly 6 ng/mL (Thorén et al., 2021). About 9 to 12% of people with European ancestry are CYP2D6 poor metabolizers (Koopmans et al., 2021). So if you have ever run tamoxifen for PCT and felt like it did nothing for your estradiol or recovery, genetics may be the reason rather than a bunk source.

The most common loss-of-function variant, CYP2D6*4 (rs3892097), is on your 23andMe file. Individualized dose escalation has been shown to restore endoxifen into the therapeutic range in poor metabolizers without extra side effects (Dezentjé et al., 2015), but that is a decision for a doctor, not a forum.

What if I'm a CYP2D6 poor metabolizer?

Say the tool flags you as carrying two reduced-function CYP2D6 copies. Here is the practical decision tree. Tamoxifen for PCT becomes a question mark, so you would discuss raloxifene (which does not depend on CYP2D6 activation) or endoxifen-guided dosing with a physician. Codeine and tramadol, both prodrugs activated by CYP2D6, will give you weak pain relief. Several beta-blockers and antidepressants metabolized by this enzyme accumulate in your system, so standard doses hit harder. None of this is something to self-correct; it is a list of things to tell any prescriber before they reach for the default dose.

SLCO1B1 and the statin that wrecks your muscles

Plenty of enhanced lifters end up on a statin for cycle-induced dyslipidemia. The SLCO1B1 gene controls how your liver takes up statins, and the *5 variant (rs4149056) is a big deal. In the landmark genome-wide study, each copy roughly quadrupled the odds of statin myopathy on high-dose simvastatin, and homozygotes carried an odds ratio near 17 (SEARCH Collaborative Group, 2008). Around 1 in 4 Europeans carries at least one risk allele.

The trap for lifters is that statin muscle pain looks exactly like training soreness, so it gets ignored until creatine kinase climbs. The genuinely useful part: the effect is strongest for simvastatin and much weaker for atorvastatin, which shows no significant association in the same analyses (Brunham et al., 2012). Knowing you carry the variant gives you a concrete conversation: ask about atorvastatin instead of simvastatin.

UGT1A1 and why your bilirubin looks terrifying when your liver is fine

This one resolves a panic that happens constantly on cycle bloodwork. Around 1 in 10 people of European ancestry carries two copies of UGT1A1*28 and has Gilbert's syndrome, a completely benign genetic condition that raises unconjugated bilirubin (Gil & Sasiadek, 2012). If your ALT and AST are normal but your bilirubin keeps coming back high, Gilbert's is the likely answer, not liver damage from your orals. Confirming it from your DNA can save you an unnecessary scare and a round of expensive follow-up testing. If you want the full picture on how oral compounds actually move liver markers, the liver enzymes on steroids guide covers it.

The rest of the panel

CYP2C19 metabolizes the blood thinner clopidogrel and acid-reflux drugs like omeprazole. Poor metabolizers fail to activate clopidogrel (an FDA black-box concern), while ultrarapid metabolizers, about 23% of Europeans, clear PPIs so fast that standard reflux doses can underperform (Brown & Pereira, 2018). CYP2C9 governs NSAIDs and warfarin; the *3 variant raises NSAID-related gastrointestinal bleeding risk substantially (Pilotto et al., 2007), which matters if you live on ibuprofen for training inflammation. CYP3A4 handles the first-pass metabolism of oral anabolic steroids; the *22 slow-metabolizer variant cuts hepatic enzyme expression by about half, so carriers may accumulate higher levels of oral compounds like oxandrolone at the same dose, though this is mechanistic plausibility rather than proven outcomes data.

Steroid metabolism quirks and hard safety flags

Beyond standard drug metabolism, a couple of variants change how your body handles steroids and stimulants specifically.

UGT2B17, testosterone clearance, and the doping-test loophole

UGT2B17 tags testosterone for urinary excretion. A common deletion makes it non-functional, and the population split is dramatic: roughly 9% of Swedish men carry the deletion versus about 67% of Korean men (Jakobsson et al., 2006). People with the deletion excrete almost no testosterone in urine, which collapses the testosterone-to-epitestosterone (T:E) ratio that anti-doping uses. In athlete cohorts, deletion carriers show a markedly lower T:E ratio than non-carriers (Martín-Escudero et al., 2015). The practical reality is uncomfortable: a large fraction of East Asian athletes could use exogenous testosterone and never trip the urine ratio, which is exactly why the biological passport and carbon isotope testing exist. The same deletion may also blunt how much your serum testosterone rises on TRT.

RET variants: the one result worth checking before a GLP-1

GLP-1 drugs like semaglutide and tirzepatide carry a boxed warning: they are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN2. The RET proto-oncogene is the gene behind those conditions, and the G691S variant turns up significantly more often in medullary thyroid cancer patients than in the general population (Elisei et al., 2004; Espinosa De Ycaza et al., 2024). With GLP-1s now everywhere in cutting protocols, this is the single genetic flag where the honest move is to check it, and if you have a family history of thyroid cancer, see an endocrinologist before you touch one.

COMT and why clenbuterol hits some people like a truck

COMT clears your catecholamines: dopamine, adrenaline, noradrenaline. The Val158Met variant (rs4680) creates a three-to-fourfold spread in enzyme activity (Lachman et al., 1996), and roughly a quarter of Europeans are slow-clearing Met/Met types whose dopamine and noradrenaline clear more slowly (Gerra et al., 2024). On a sympathomimetic like clenbuterol or a heavy pre-workout, a Met/Met carrier hangs onto those catecholamines far longer, which can mean exaggerated tachycardia, tremor and anxiety at a dose someone else shrugs off. If stimulants always seem to floor you, this variant is a plausible reason.

Training and injury genetics

Now the part everyone actually wants to look up first. A word of caution before the gene names: these effects are real but small. Every association below comes from population statistics, and the overlap between genotype groups is enormous. Your genotype shifts the odds; it does not set your ceiling.

ACTN3, the "speed gene"

ACTN3 builds alpha-actinin-3, a protein in fast-twitch muscle fibers. The R577X variant (rs1815739) comes in three flavors: RR, RX, and XX, where XX produces no functional protein. The 2024 meta-analysis found RR is modestly overrepresented in power athletes versus controls, odds ratio around 1.48, and XX is underrepresented (El Ouali et al., 2024). Sounds decisive until you see the distribution: nearly 1 in 7 elite power athletes is actually XX. The same authors state plainly that ACTN3 genotyping should not be used to identify talent. What XX more reliably predicts is higher exercise-induced muscle damage and slower recovery (Baltazar-Martins et al., 2020), which is a programming note, not a verdict on your potential.

COL5A1 and your tendons

This is the most genuinely actionable training variant. COL5A1 codes for type V collagen in your tendons and ligaments, and the rs12722 TT genotype is tied to a 58% higher risk of soft-tissue injury, including Achilles and ACL problems (Lv et al., 2018). For a lifter on anabolics, this compounds a known problem: steroids build contractile strength faster than connective tissue can adapt. If you carry TT, the takeaway is concrete: respect tendon adaptation timelines, lean on tempo and eccentric work, and stop adding plates faster than your tendons can follow.

ACE and PPARGC1A

The ACE I/D polymorphism skews toward endurance (II) or power (DD), with the II genotype enriched in elite endurance athletes (Sommers et al., 2024). PPARGC1A regulates mitochondrial biogenesis, and the Gly/Gly genotype is modestly favored across both endurance and power athletes (Chen et al., 2019). The Ser allele also tracks with worse insulin sensitivity, which connects to the next section: if you carry it and you are stacking MK-677, GH or insulin, watch your glucose closely. The GH and insulin resistance guide goes deeper on that interaction.

Nutrition, methylation, and cardiovascular risk

MTHFR, the most overhyped result in your file

You will see MTHFR everywhere in the supplement world, so here is the honest version. The C677T variant (rs1801133) does reduce enzyme activity: the TT genotype runs at roughly 25 to 35% of normal and raises homocysteine (Raghubeer & Matsha, 2021). That biology is real. What is not real is most of what gets sold off the back of it. The American College of Medical Genetics explicitly recommends against routine MTHFR testing, because the genotype is a weak standalone predictor and the large trials lowering homocysteine with B vitamins did not reduce cardiovascular events (Hickey et al., 2013). The sensible move is to measure homocysteine and B12 directly rather than treat a gene result. Folate and B12 are cheap and safe, so supplementing is reasonable; the "MTHFR detox protocol" upsell is not.

APOE, lipids, and why genetics plus orals is a bad combination

Your APOE genotype (e2, e3, e4) shapes how you clear LDL. The e4 allele impairs LDL clearance, raising total cholesterol and oxidized LDL and adding a pro-inflammatory tilt (Jofre-Monseny et al., 2008). Now layer that on the known lipid carnage of oral steroids: 17-alpha-alkylated orals drop HDL by around half and raise LDL by a third on average (Glazer, 1991). An athlete who genetically clears LDL poorly and then runs orals has no buffer. If you have a family history of early heart disease, or your total cholesterol stays high on a clean diet, that is a flag worth taking seriously before another oral cycle.

What your DNA absolutely cannot tell you

This is the section that keeps you honest, and it matters most for fertility, where false reassurance is dangerous. Consumer arrays are blind to the high-yield causes of male infertility by design.

The one genuinely useful fertility result is CFTR carrier status. Around 1 in 25 Europeans carries a CFTR mutation, usually F508del, and 23andMe reports it (Fedder et al., 2021). A single carrier result does not mean you are infertile; it matters mainly for pre-conception planning with a partner. The thrombophilia variants you will also see, Factor V Leiden and Prothrombin G20210A, are popular to check. Some studies do link them to unexplained infertility (Fatini et al., 2012), but the associations are modest and contested, and major guideline bodies like ASRM do not recommend routine thrombophilia screening as part of a fertility workup.

Here is what a SNP array genuinely cannot see:

• Y-chromosome microdeletions, found in 15 to 20% of azoospermic men. Consumer arrays do not even cover the Y chromosome's relevant regions (Witherspoon et al., 2021).
• Balanced translocations, which cause infertility but show no copy-number change, so a SNP chip is blind to them. You need a karyotype.
• Fragile X CGG repeat expansions, which are structurally invisible to genotyping arrays.
• Sperm count and motility. No gene predicts these. A semen analysis does.

And the big one for this audience: the most common reason a PED user goes infertile is not in their DNA at all. Testosterone and AAS suppress the HPG axis, and 93 to 99% of men go azoospermic within three months of testosterone therapy; most recover within a year of stopping, but not all (Al Hashimi et al., 2025). A clean genetic report tells you nothing about this. If fertility is the question, a semen analysis comes first, then a hormone panel, then genetic and karyotype testing only if those stay abnormal. The HCG and fertility on TRT guide walks through preserving your options, and the dedicated fertility DNA test page explains exactly what the genetic side can and cannot cover.

How to run it

Log into VitalMetrics, open the DNA analysis tool, and drag in the raw data file you downloaded. The analysis runs in your browser in a second or two, sorts results into pharmacogenomics, exercise, nutrition, health risk and fertility, and links flagged variants to the relevant compound and marker pages so you can read the full context. Pair it with actual bloodwork: genetics tells you the starting conditions, your labs tell you what is happening now. The complete bloodwork guide is the place to build the testing side of that picture, and the PCT bloodwork guide is worth reading alongside your CYP2D6 result.

Key takeaways

• Your existing raw DNA file already contains pharmacogenomic variants. The standard dose was built for average metabolism, not yours.
• CYP2D6 decides whether tamoxifen converts to its active form; about 1 in 10 Europeans is a poor metabolizer who barely activates it.
• SLCO1B1 (statin myopathy, ~1 in 4 carriers) and UGT1A1 (Gilbert's syndrome, the benign cause of high bilirubin) are the most immediately useful flags on cycle.
• Check RET before starting a GLP-1 if you have any family history of thyroid cancer.
• Training genes like ACTN3 and ACE have real but small effects; COL5A1 (tendon injury risk) is the one most worth acting on.
• Consumer DNA cannot see Y-microdeletions, balanced translocations, Fragile X or sperm quality. For fertility, a semen analysis comes first, every time.
• Analyze the file in your browser, never upload it, and take any flag to a clinician for confirmation.

---

References

1. Thorén, L., Lindh, J. D., Ackehed, G., et al. (2021). Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. British Journal of Clinical Pharmacology, 87(3), 1243-1252. PubMed
2. Dezentjé, V. O., Opdam, F. L., Gelderblom, H., et al. (2015). CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation. Breast Cancer Research and Treatment, 153(3), 583-590. PubMed
3. Koopmans, A. B., Braakman, M. H., Vinkers, D. J., Hoek, H. W., & van Harten, P. N. (2021). Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Translational Psychiatry, 11, 141. PubMed
4. SEARCH Collaborative Group. (2008). SLCO1B1 variants and statin-induced myopathy: A genomewide study. New England Journal of Medicine, 359(8), 789-799. PubMed
5. Brunham, L. R., Lansberg, P. J., Zhang, L., et al. (2012). Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics Journal, 12(3), 233-237. PubMed
6. Gil, J., & Sasiadek, M. M. (2012). Gilbert syndrome: The UGT1A1*28 promoter polymorphism as a biomarker. Biomarkers in Medicine, 6(2), 223-230. PubMed
7. Brown, S. A., & Pereira, N. (2018). Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy. Journal of Personalized Medicine, 8(1), 8. PubMed
8. Pilotto, A., Seripa, D., Franceschi, M., et al. (2007). Genetic susceptibility to NSAID-related gastroduodenal bleeding: Role of CYP2C9 polymorphisms. Gastroenterology, 133(2), 465-471. PubMed
9. Jakobsson, J., Ekström, L., Inotsume, N., et al. (2006). Large differences in testosterone excretion in Korean and Swedish men are associated with a UGT2B17 polymorphism. Journal of Clinical Endocrinology & Metabolism, 91(2), 687-693. PubMed
10. Martín-Escudero, P., Muñoz-Guerra, J., Del Prado, N., et al. (2015). Impact of UGT2B17 gene deletion on the steroid profile of an athlete. Physiological Reports, 3(12), e12631. PubMed
11. Elisei, R., Cosci, B., Romei, C., et al. (2004). RET exon 11 (G691S) polymorphism is more frequent in sporadic medullary thyroid carcinoma. Journal of Clinical Endocrinology & Metabolism, 89(7), 3579-3584. PubMed
12. Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., et al. (2024). Glucagon-like peptide-1 receptor agonists and thyroid cancer: A narrative review. Thyroid, 34(4), 409-421. PubMed
13. Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y. M., Szumlanski, C. L., & Weinshilboum, R. M. (1996). Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics, 6(3), 243-250. PubMed
14. Gerra, M. C., Dallabona, C., Manfredini, M., et al. (2024). The polymorphism Val158Met in the COMT gene: disrupted dopamine system. Pain, 165(9), 1993-2004. PubMed
15. El Ouali, E. M., Barthelemy, B., Del Coso, J., et al. (2024). A systematic review and meta-analysis of the association between ACTN3 R577X genotypes and performance. Sports Medicine - Open, 10, 37. PubMed
16. Baltazar-Martins, G., Gutiérrez-Hellín, J., Aguilar-Navarro, M., et al. (2020). Effect of ACTN3 genotype on sports performance, muscle damage, and injury epidemiology. Sports (Basel), 8(7), 99. PubMed
17. Lv, Z. T., Gao, S. T., Cheng, P., et al. (2018). Association between rs12722 in COL5A1 and musculoskeletal soft tissue injuries: A meta-analysis. Oncotarget, 9(20), 15365-15374. PubMed
18. Sommers, L., Akam, L., Hunter, D. J., Bhatti, J. S., & Mastana, S. (2024). Role of the ACE I/D polymorphism in sporting modalities: An updated meta-analysis. International Journal of Environmental Research and Public Health, 21(11), 1439. PubMed
19. Chen, Y., Wang, D., Yan, P., et al. (2019). Meta-analyses of the association between the PPARGC1A Gly482Ser polymorphism and athletic performance. Biology of Sport, 36(4), 301-309. PubMed
20. Raghubeer, S., & Matsha, T. E. (2021). MTHFR, the one-carbon cycle, and cardiovascular risks. Nutrients, 13(12), 4562. PubMed
21. Hickey, S. E., Curry, C. J., & Toriello, H. V. (2013). ACMG practice guideline: Lack of evidence for MTHFR polymorphism testing. Genetics in Medicine, 15(2), 153-156. PubMed
22. Jofre-Monseny, L., Minihane, A.-M., & Rimbach, G. (2008). Impact of apoE genotype on oxidative stress, inflammation and disease risk. Molecular Nutrition & Food Research, 52(1), 131-145. PubMed
23. Glazer, G. (1991). Atherogenic effects of anabolic steroids on serum lipid levels: A literature review. Archives of Internal Medicine, 151(10), 1925-1933. PubMed
24. Fedder, J., Jørgensen, M. W., & Engvad, B. (2021). Prevalence of CBAVD in azoospermic men carrying pathogenic CFTR mutations. Andrology, 9(2), 588-598. PubMed
25. Fatini, C., Conti, L., Turillazzi, V., et al. (2012). Unexplained infertility: association with inherited thrombophilia. Thrombosis Research, 129(5), e185-e188. PubMed
26. Witherspoon, L., Dergham, A., & Flannigan, R. (2021). Y-microdeletions: a review of the genetic basis for male infertility. Translational Andrology and Urology, 10(3), 1383-1390. PubMed
27. Al Hashimi, M., Pinggera, G. M., Shah, R., & Agarwal, A. (2025). Clinician's guide to azoospermia induced by exogenous testosterone or anabolic-androgenic steroids. Asian Journal of Andrology. PubMed